ARTICLE | Clinical News
DexaSite dexamethasone: Completed Phase III enrollment
September 24, 2012 7:00 AM UTC
InSite completed enrollment of over 900 patients the double-blind, U.S. DOUBle Phase III trial to evaluate AzaSite Plus and DexaSite. Patients are receiving AzaSite Plus, DexaSite, AzaSite or the DuraSite vehicle twice daily for 14 days. InSite has an SPA from FDA for DOUBle. ...